LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY
EHA Learning Center, Marius Flasinski, 182076
21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)
EHA Learning Center, Karl Staser, 182081
IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Masafumi Seki, 182086
DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)
EHA Learning Center, Ildefonso Espigado, 182091
LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION.
EHA Learning Center, Sandro , 182096
A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL
EHA Learning Center, Mark Walters, 182101
T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT
EHA Learning Center, Long Liu, 181793
RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL
EHA Learning Center, Yuan Kong, 181794
PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING
EHA Learning Center, Felix Seyfried, 181795
CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA
EHA Learning Center, Lucia Fernandez, 181796
A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR
EHA Learning Center, Africa Gonzalez-Murillo, 181797
CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSPR2) TRANSCRIPT LEVELS CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NORMAL CYTOGENETICS
EHA Learning Center, Shu-Juan Wang, 181798
THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Ali Alhammer, 181799
BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME
EHA Learning Center, Lidia M Fernández-Sevilla, 181800
TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Anne BUFFIERE, 181801
SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL
EHA Learning Center, Marina Kunstreich, 181802
FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS
EHA Learning Center, Dr. Fabian Lang, 181803
ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
EHA Learning Center, Shannon Maude, 181804
UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Nicholas Short, 181805
PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN
EHA Learning Center, Elias J Jabbour, 181806
A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS
EHA Learning Center, Renato , 181807
BLINATUMOMAB USE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY
EHA Learning Center, Franco Locatelli, 181808
PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)
EHA Learning Center, Frederick L. Locke, 181809
KTE-C19 CHIMERIC ANTIGENRECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3
EHA Learning Center, Bijal Shah, 181810
EXPOSURE-ADJUSTED ADVERSE EVENTS COMPARING BLINATUMOMAB WITH STANDARD OF CARE CHEMOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A RANDOMIZED PHASE 3 STUDY
EHA Learning Center, Max S.Topp, 181811
FACTORS ASSOCIATED WITH STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN VERSUS CONVENTIONAL CHEMOTHERAPY
EHA Learning Center, Matthias Stelljes, 181812
DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS
EHA Learning Center, Sharlene Adams, 181813
THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION
EHA Learning Center, Robert Slany, 181814
PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.
EHA Learning Center, Daniela Di Marcantonio, 181815
ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2
EHA Learning Center, Ruchi Pandey, 181817
CLUSTER REGULATION OF RUNX FAMILY BY “GENE SWITCH” TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS.
EHA Learning Center, Ken Morita, 181818
PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS
EHA Learning Center, Pedro Casado-Izquierdo, 181819
CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Frauke Theis, 181820
GFI1B - A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS
EHA Learning Center, Aniththa Thivakaran, 181821
VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB
EHA Learning Center, Mridul Agrawal, 181822
P38Β MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Elena Arriazu, 181823
GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA
EHA Learning Center, June Takeda, 181824
THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES
EHA Learning Center, Adil Al Hinai, 181825
EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML
EHA Learning Center, James Smith, 181826
NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA
EHA Learning Center, I-Jun Lau, 181827
CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Sneha CHITRE, 181828
TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML
EHA Learning Center, Iris Uras, 181829
CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.
EHA Learning Center, Mayte Medrano, 181830
PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Elisa Sala, 181831
AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?
EHA Learning Center, Victoria Prassek, 181833
GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE
EHA Learning Center, Daniel J. DeAngelo, 181834
BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY
EHA Learning Center, Tsila Zuckerman, 181835
FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES
EHA Learning Center, Claudia Haferlach, 181836
COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
EHA Learning Center, Kiyomi Morita, 181837
THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY
EHA Learning Center, Daehun kwak, 181838
VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML
EHA Learning Center, Eunice Wang, 181839
PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH '7+3' DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD
EHA Learning Center, Dr. Medhavi Gupta, 181840
VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL.
EHA Learning Center, Ballesteros Juan, 181841
RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS > 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP
EHA Learning Center, Haifa Kathrin Al-Ali, 181842
OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY
EHA Learning Center, Jeffrey Lancet, 181843
HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Sarah Bertoli, 181844
NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE - IMPACT OF AGE ON MUTATIONAL LOAD
EHA Learning Center, Lisa Pleyer, 181845
PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY
EHA Learning Center, Sigrid Machherndl-Spandl, 181846
EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT WITH GILTERITINIB
EHA Learning Center, Mark Levis, 181847
CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION
EHA Learning Center, Daehun kwak, 181848
INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Learning Center, Jorge Cortes, 181849
COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA
EHA Learning Center, Matthew A. Lunning, 181850
VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
EHA Learning Center, Matthew S. Davids, 181851
WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA
EHA Learning Center, Katja De Paepe, 181852
PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.
EHA Learning Center, Joost Vermaat, 181854
HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY
EHA Learning Center, Marcus Hentrich, 181855
RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA
EHA Learning Center, Deok-Hwan Yang, 181856
LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES.
EHA Learning Center, Francesca Farina, 181857
PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.
EHA Learning Center, Catherine Scholz, 181858
BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC).
EHA Learning Center, Jérôme Jérôme, 181859
ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
EHA Learning Center, Raul Teruel, 181860
SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA
EHA Learning Center, Francesca Fioredda, 181862
TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS
EHA Learning Center, Constantijn J.M. Halkes, 181863
IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
EHA Learning Center, Xuying Pei, 181864
DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY
EHA Learning Center, Mirkka Schaller, 181865
DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS.
EHA Learning Center, Birgit van Dooijeweert, 181866
NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES
EHA Learning Center, Eva Galvez, 181867
APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY
EHA Learning Center, Emilie Nevill, 181868
RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS
EHA Learning Center, Maren Oelmüller, 181869
NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
EHA Learning Center, Federico , 181870
CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.
EHA Learning Center, Julia Almeida, 181871
NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES
EHA Learning Center, Andrejs Braun, 181872
MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Fortunato Morabito, 181873
IL-4 INCREASES EXPRESSION OF POSITIVE REGULATORS OF BCR SIGNALLING IN CLL WHICH CAN BE OVERCOME BY CERDULATINIB
EHA Learning Center, Matthew Blunt, 181874
INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE
EHA Learning Center, Erika Tissino, 181875
IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY
EHA Learning Center, Talha Munir, 181876
EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53
EHA Learning Center, Sean Post, 181877
THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Mhairi Copland, 181878
SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS
EHA Learning Center, Jun Toda, 181879
TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT
EHA Learning Center, Anne-Sophie Bouillon, 181880
GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS PREEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION TO BLASTIC PHASE INDEPENDENTLY OF BCR-ABL1 MUTATIONS
EHA Learning Center, Marcin Machnicki, 181881
INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE
EHA Learning Center, Sieghart Sopper, 181882
BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB
EHA Learning Center, Konstantin Byrgazov, 181883
IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO.
EHA Learning Center, Robert Peter Gale, 181884
MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY
EHA Learning Center, Francesco Albano, 181885
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.
EHA Learning Center, sara galimberti, 181886
ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS
EHA Learning Center, Manuela Mancini, 181887
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
EHA Learning Center, David Ross, 181888
RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT
EHA Learning Center, Niels Pallisgaard, 181889
5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
EHA Learning Center, Jorge E Cortes, 181890